Global Clinical Oncology Next Generation Sequencing Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

Description

List of Tables

The global demand for Clinical Oncology Next Generation Sequencing Market is presumed to reach the market size of nearly USD 1406.19 MN by 2030 from USD 421.6 MN in 2022 with a CAGR of 16.25% under the study period 2023 - 2030.

Clinical oncology next generation sequencing (NGS) refers to the application of advanced genomic sequencing technologies in the field of oncology (cancer care and treatment). It enables the comprehensive analysis of a patient's tumor DNA or RNA to identify genetic alterations, mutations, or variations that drive cancer development, progression, and response to treatments.

MARKET DYNAMICS

Technological advancements in next generation sequencing, marked by enhanced accuracy, faster sequencing, and reduced costs, drive its adoption in clinical oncology. The paradigm shift towards personalized medicine and precision oncology amplifies its use for analyzing tumor genetics, facilitating tailored treatment strategies based on individual genetic profiles. The escalating incidence of cancer globally fuels the demand for advanced diagnostic tools like NGS, aiding accurate tumor profiling and treatment decisions. NGS also plays a pivotal role in cancer research, identifying new biomarkers and therapeutic targets, and driving its incorporation into clinical studies and trials. Healthcare providers increasingly integrate NGS-based tests into routine clinical practice for cancer diagnosis, prognosis, and treatment selection. Supportive regulatory environments and established guidelines validate next generation sequencing applications, ensuring quality and reliability in clinical settings. Partnerships and collaborations between technology providers, pharmaceutical companies, and research institutions foster innovation, product development, and wider accessibility to NGS-based oncology tests.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of clinical oncology next generation sequencing. The growth and trends of clinical oncology next generation sequencing industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the clinical oncology next generation sequencing market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Technology

Whole Genome Sequencing
Whole Exome Sequencing
Targeted Sequencing & Resequencing

By Workflow

NGS Pre-Sequencing
NGS Sequencing
NGS Data Analysis

By Application

Screening (Sporadic Cancer, Inherited Cancer)
Companion Diagnostics
Other Diagnostics

By End-Use

Hospitals
Clinics
Laboratories

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Clinical Oncology Next Generation Sequencing market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Clinical Oncology Next Generation Sequencing market include Illumina Inc., Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd., Agilent Technologies, Myriad Genetics, Beijing Genomics Institute (BGI), Perkin Elmer, Foundation Medicine, Pacific Bioscience, Oxford Nanopore Technologies Ltd., Paradigm Diagnostics, Caris Life Sciences, Partek Inc., Eurofins Scientific S.E., Qiagen N.V. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112112976

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Technology
- 3.7.2 Market Attractiveness Analysis By Workflow
- 3.7.3 Market Attractiveness Analysis By Application
- 3.7.4 Market Attractiveness Analysis By End-use
- 3.7.5 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET ANALYSIS BY TECHNOLOGY

5.1 Overview by Technology
5.2 Historical and Forecast Data
5.3 Analysis by Technology
5.4 Whole Genome Sequencing Historic and Forecast Sales by Regions
5.5 Whole Exome Sequencing Historic and Forecast Sales by Regions
5.6 Targeted Sequencing & Resequencing Historic and Forecast Sales by Regions

6 . GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET ANALYSIS BY WORKFLOW

6.1 Overview by Workflow
6.2 Historical and Forecast Data
6.3 Analysis by Workflow
6.4 NGS Pre-Sequencing Historic and Forecast Sales by Regions
6.5 NGS Sequencing Historic and Forecast Sales by Regions
6.6 NGS Data Analysis Historic and Forecast Sales by Regions

7 . GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET ANALYSIS BY APPLICATION

7.1 Overview by Application
7.2 Historical and Forecast Data
7.3 Analysis by Application
7.4 Screening (Sporadic Cancer, Inherited Cancer) Historic and Forecast Sales by Regions
7.5 Companion Diagnostics Historic and Forecast Sales by Regions
7.6 Other Diagnostics Historic and Forecast Sales by Regions

8 . GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET ANALYSIS BY END-USE

8.1 Overview by End-use
8.2 Historical and Forecast Data
8.3 Analysis by End-use
8.4 Hospitals Historic and Forecast Sales by Regions
8.5 Clinics Historic and Forecast Sales by Regions
8.6 Laboratories Historic and Forecast Sales by Regions

9 . GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook
9.2. Introduction
9.3. North America Sales Analysis
- 9.3.1. Overview, Historic and Forecast Data Sales Analysis
- 9.3.2. North America By Segment Sales Analysis
- 9.3.3. North America By Country Sales Analysis
- 9.3.4. United State Sales Analysis
- 9.3.5. Canada Sales Analysis
- 9.3.6. Mexico Sales Analysis
9.4. Europe Sales Analysis
- 9.4.1. Overview, Historic and Forecast Data Sales Analysis
- 9.4.2. Europe by Segment Sales Analysis
- 9.4.3. Europe by Country Sales Analysis
- 9.4.4. United Kingdom Sales Analysis
- 9.4.5. France Sales Analysis
- 9.4.6. Germany Sales Analysis
- 9.4.7. Italy Sales Analysis
- 9.4.8. Russia Sales Analysis
- 9.4.9. Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
- 9.5.1. Overview, Historic and Forecast Data Sales Analysis
- 9.5.2. Asia Pacific by Segment Sales Analysis
- 9.5.3. Asia Pacific by Country Sales Analysis
- 9.5.4. China Sales Analysis
- 9.5.5. India Sales Analysis
- 9.5.6. Japan Sales Analysis
- 9.5.7. South Korea Sales Analysis
- 9.5.8. Australia Sales Analysis
- 9.5.9. South East Asia Sales Analysis
- 9.5.10. Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
- 9.6.1. Overview, Historic and Forecast Data Sales Analysis
- 9.6.2. Latin America by Segment Sales Analysis
- 9.6.3. Latin America by Country Sales Analysis
- 9.6.4. Brazil Sales Analysis
- 9.6.5. Argentina Sales Analysis
- 9.6.6. Peru Sales Analysis
- 9.6.7. Chile Sales Analysis
- 9.6.8. Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
- 9.7.1. Overview, Historic and Forecast Data Sales Analysis
- 9.7.2. Middle East & Africa by Segment Sales Analysis
- 9.7.3. Middle East & Africa by Country Sales Analysis
- 9.7.4. Saudi Arabia Sales Analysis
- 9.7.5. UAE Sales Analysis
- 9.7.6. Israel Sales Analysis
- 9.7.7. South Africa Sales Analysis
- 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING COMPANIES

10.1. Clinical Oncology Next Generation Sequencing Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11 . COMPANY PROFILES OF CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING INDUSTRY

11.1. Company Share Analysis
11.2. Market Concentration Rate
11.3. Illumina Inc.
- 11.3.1. Company Overview
- 11.3.2. Company Revenue
- 11.3.3. Products
- 11.3.4. Recent Developments
11.4. Thermo Fisher Scientific
- 11.4.1. Company Overview
- 11.4.2. Company Revenue
- 11.4.3. Products
- 11.4.4. Recent Developments
11.5. F. Hoffmann-La Roche Ltd.
- 11.5.1. Company Overview
- 11.5.2. Company Revenue
- 11.5.3. Products
- 11.5.4. Recent Developments
11.6. Agilent Technologies
- 11.6.1. Company Overview
- 11.6.2. Company Revenue
- 11.6.3. Products
- 11.6.4. Recent Developments
11.7. Myriad Genetics
- 11.7.1. Company Overview
- 11.7.2. Company Revenue
- 11.7.3. Products
- 11.7.4. Recent Developments
11.8. Beijing Genomics Institute (BGI)
- 11.8.1. Company Overview
- 11.8.2. Company Revenue
- 11.8.3. Products
- 11.8.4. Recent Developments
11.9. Perkin Elmer
- 11.9.1. Company Overview
- 11.9.2. Company Revenue
- 11.9.3. Products
- 11.9.4. Recent Developments
11.10. Foundation Medicine
- 11.10.1. Company Overview
- 11.10.2. Company Revenue
- 11.10.3. Products
- 11.10.4. Recent Developments
11.11. Pacific Bioscience
- 11.11.1. Company Overview
- 11.11.2. Company Revenue
- 11.11.3. Products
- 11.11.4. Recent Developments
11.12. Oxford Nanopore Technologies Ltd.
- 11.12.1. Company Overview
- 11.12.2. Company Revenue
- 11.12.3. Products
- 11.12.4. Recent Developments
11.13. Paradigm Diagnostics
- 11.13.1. Company Overview
- 11.13.2. Company Revenue
- 11.13.3. Products
- 11.13.4. Recent Developments
11.14. Caris Life Sciences
- 11.14.1. Company Overview
- 11.14.2. Company Revenue
- 11.14.3. Products
- 11.14.4. Recent Developments
11.15. Partek Inc.
- 11.15.1. Company Overview
- 11.15.2. Company Revenue
- 11.15.3. Products
- 11.15.4. Recent Developments
11.16. Eurofins Scientific S.E.
- 11.16.1. Company Overview
- 11.16.2. Company Revenue
- 11.16.3. Products
- 11.16.4. Recent Developments
11.17. Qiagen N.V.
- 11.17.1. Company Overview
- 11.17.2. Company Revenue
- 11.17.3. Products
- 11.17.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies